Bi Asset Management Fondsmaeglerselskab A Rhythm Pharmaceuticals, Inc. Transaction History
Bi Asset Management Fondsmaeglerselskab A
- $8.88 Billion
- Q1 2025
A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 648 shares of RYTM stock, worth $40,603. This represents 0.0% of its overall portfolio holdings.
Number of Shares
648Holding current value
$40,603% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RYTM
# of Institutions
245Shares Held
62.9MCall Options Held
403KPut Options Held
62.8K-
Black Rock Inc. New York, NY6.74MShares$422 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$381 Million6.69% of portfolio
-
Primecap Management CO Pasadena, CA5.79MShares$363 Million0.26% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$351 Million3.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$216 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.49B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...